CliffBio
small molecule

BIMATOPROST

BIMATOPROST

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBIMATOPROST
Active ingredientBIMATOPROST
Strength0.03%
Dosage formSOLUTION/DROPS
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2014
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.